Abstract
Osteoporosis in men is an important, but underappreciated, public health problem. In the Phase 3 ACTIVE study in postmenopausal women with osteoporosis, abaloparatide (ABL) significantly increased bone mineral density (BMD), and decreased risk of vertebral, nonvertebral, and clinical fractures vs placebo (PBO), and major osteoporotic fracture vs teriparatide and PBO. The Abaloparatide for the Treatment of Men with Osteoporosis (ATOM) randomized, double-blind, placebo-controlled, phase 3 study evaluated efficacy and safety of ABL vs PBO for osteoporosis treatment in men.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
